Objective:

2

To observe the clinical efficacy of modified Xiaofengsan and its effect on cytokines in persistent asthma patients with wind-asthma pattern.

Method:

2

The 120 eligible patients with chronic and persistent asthma were randomly divided into control group (60 cases) and treatment group (60 cases). Patients in control group received the budesonide/formoterol (160 μg/4.5 μg

2 inhales/time

bid

). Patients in treatment group additionally received the modified Xiaofengsan combined with budesonide/formoterol (160 μg/4.5 μg). The treatment course was 1 month in both groups. The clinical efficacy of the two groups was observed. Before and 3 months after treatment

asthma control test (ACT) and the average times of acute exacerbation in 6 months before and after treatment between two groups were observed; percentage of forced expiratory volume in first second and its predicted value (FEV

1

%)

variety ratio of Peak expiratory flow (PEF)

eosinophilic granulocyte (EOS) count in peripheral blood and the levels of interleukin-4(IL-4)

interleukin-6(IL-6) and interleukin-13(IL-13) in serum were measured before and after treatment respectively. In addition

the safety of the two groups was evaluated.

Result:

2

The total effective rate of the treatment group was higher than that of the control group (

P

<

0.05). The levels of ACT value and FEV

1

% in treatment group were higher(

P

<

0.05)

while the average times of acute exacerbation

PEF variety ratio

EOS count in peripheral blood

L-4

IL-6 and IL-13 in serum were lower(

P

<

0.05) than those in control group after treatment. There was no significant difference in incidence of the adverse reactions.

Conclusion:

2

Modified Xiaofengsan combined with budesonide/formoterol could relieve symptoms of asthma

improve pulmonary function and lower the levels of IL-4

IL-6 and IL-13 in serum.